CEL-SCI Corporation has announced the completion of its Breakthrough Medicine Designation application for Multikine, an investigational immunotherapy for head and neck cancer, to the Saudi Food and Drug Authority (SFDA). The application is expected to be formally submitted within the next few weeks by CEL-SCI's prospective Saudi partner, a leading pharmaceutical and healthcare company in the country. A response from the SFDA is anticipated within approximately 60 days. If granted, Multikine could become available for patient access and commercial use in Saudi Arabia by the summer of 2025. The treatment has demonstrated a significant increase in the 5-year survival rate for the target patient population.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。